Phaseline

Companies › Brain Neurotherapy Bio

Brain Neurotherapy Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV2-GDNF
AAV2-delivered GDNF gene therapy
GDNFPhase 1Parkinson's Disease; Multiple System AtrophyJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04167540AAV2-GDNFPhase 1Parkinson's DiseaseNeurologyJun 2027
NCT04680065AAV2-GDNFPhase 1Multiple System AtrophyNeurologyAug 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GDNF (1)

Companies with the same targets

AskBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.